[
  {
    "clause_index": 0,
    "start_char": 0,
    "end_char": 97,
    "original": "Exhibit 10.1 COLOGUARD\u00ae PROMOTION AGREEMENT BY AND BETWEEN EXACT SCIENCES CORPORATION PFIZER INC.",
    "ollama_generated": "Exhibit 10.1 COLOGUARD^{\u00ae} PROMOTION AGREEMENT AMENDMENT\n\nBETWEEN:\nEXACT SCIENCES CORPORATION (hereinafter \"Exact Sciences\")\nand\nPFIZER INC. (hereinafter \"Pfizer\")\n\nIn the event that Exact Sciences deems it necessary to alter or discontinue its marketing strategies, Pfizer shall have no obligation to modify or adjust its promotional efforts in accordance with such changes, unless explicitly agreed upon in writing by both parties subsequent to this agreement. Furthermore, any claims arising from the termination or modification of the promotion by Exact Sciences shall be exclusively liable to Exact Sciences, absolving Pfizer from any liability or responsibility related thereto.",
    "contradiction_score": 0.11897970736026764,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 5,
    "start_char": 4102,
    "end_char": 4118,
    "original": "1.  DEFINITIONS.",
    "ollama_generated": "1. INTERPRETATION.\n\nFor the purpose of this Agreement, unless the context otherwise requires:\n\n\"Party\" shall mean either Company or Client, as the context may indicate;\n\n\"Agreement\" shall mean this entire document, including any appendices, amendments, and exhibits referenced herein;\n\n\"Company\" shall mean ABC Corporation, a corporation duly organized and existing under the laws of State X, with its principal place of business located at City Y;\n\n\"Client\" shall mean the individual or entity identified in the Purchase Order as the Client, who enters into this Agreement with Company for the Services;\n\n\"Services\" shall encompass all services to be performed by Company under this Agreement as set forth in the Purchase Order or any subsequent amendments, addenda, or change orders, as may be executed by the Parties.\n\nWhile maintaining a similar structure and meaning, this revised interpretation clause is intended to provide flexibility in assigning roles and responsibilities between the two parties (Company and Client) based on context. Additionally, it clarifies that any subsequent amendments, addenda, or change orders are considered part of the Agreement.",
    "contradiction_score": 0.0031450383830815554,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 9,
    "start_char": 5497,
    "end_char": 5564,
    "original": "1.4  \u201cAgreement \u201d shall have the meaning set forth in the preamble.",
    "ollama_generated": "1.4 \"The Term 'Agreement' as used herein, refers to the understanding encompassed within the introductory paragraph.\"\n\nIn this version, the meaning of 'Agreement' remains the same but is rephrased to provide a slightly more conversational tone and avoid repetition of the term 'preamble'.",
    "contradiction_score": 0.013864072971045971,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 28,
    "start_char": 9124,
    "end_char": 9557,
    "original": "1.23  \u201cCo-Promote Field \u201d shall mean those physicians and practices customarily considered primary care or gastroenterology providers and practices and, subject to Sections 3.1(c)(ii) and 4.2(d), the OB/Gyn Field, in the Territory. For clarity, if Exact, either through its own Sales Representative or by agreement with a Third Party, launches the Product in the OB/Gyn Field, the Co-Promote Field shall not include the OB/Gyn Field.",
    "ollama_generated": "1.23  \"Co-Promotion Scope\" denotes those physicians and practices generally recognized as primary care or gastroenterology providers and establishments, except for the OB/Gyn Specialty, within the Territory, on the condition that neither Exact nor its Third Party associates initiate product promotion in the OB/Gyn Specialty. In cases where Exact introduces the Product into the OB/Gyn Specialty through its own Sales Representative or a contractual arrangement with another entity, the Co-Promotion Scope will exclude the OB/Gyn Specialty.\n\nIn this revised clause, the original \"Co-Promote Field\" has been renamed to \"Co-Promotion Scope\", and the scope of the field has been slightly narrowed by excluding the OB/Gyn Specialty if Exact or its Third Party partners do not promote the product in that area. This change subtly implies a broader definition of the field, but with the responsibility for excluding the OB/Gyn Specialty shifting from Exact to other parties who choose to promote the product in that area.",
    "contradiction_score": 0.10140825062990189,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 30,
    "start_char": 9784,
    "end_char": 9862,
    "original": "1.25  \u201cDebarred/Excluded \u201d shall have the meaning set forth in Section 5.1(g).",
    "modified": "1.25 \"Permitted\" shall refer to the scope defined in Section 5.1(g). This implies that any action, individual or entity, falling within this definition is not subject to exclusion or debarment under the terms of this agreement.",
    "contradiction_score": 0.8275610208511353,
    "kept": true
  },
  {
    "clause_index": 31,
    "start_char": 9862,
    "end_char": 11896,
    "original": "1.26  \u201cDetail \u201d shall mean a customary face-to-face or non-face-to-face contact of a Sales Representative of a Party with an Eligible Prescriber during which such Sales Representative makes a presentation of certain of the Product\u2019s attributes, such as describing the FDA-approved indicated uses, safety, effectiveness, or other relevant characteristics of the Product, in a fair and balanced manner and in accordance with the requirements of this Agreement and Applicable Law and in a manner that is customary for the purpose of Promoting a prescription medical device subject to pre-market approval, but excluding: (a) any activities performed by any Representative other than a Sales Representative who is not conducting a face-to-face or non-face- to-face sales call, (b) presentations made at conventions or (c) mere delivery of savings cards, coupons or similar items without discussions with an Eligible Prescriber about the Product\u037e provided  that, such measurement shall be on the same basis as the recording Party\u2019s measurement for its Sales Representatives\u2019 detailing of its other medical devices subject to pre-market approval or prescription pharmaceutical products (as applicable), consistently applied throughout the Term. For clarity, non- face-to-face contact shall mean e-detailing, video detailing or other presentation of Promotional Material by a Sales Representative to an Eligible Prescriber via audio, video, internet, using webex or other similar live conference applications, and in all instances that allows for real time, detailed and substantive communication between the Sales Representative and the Eligible Prescriber regarding the Product and would be considered a Detail by Pfizer for its own products under its own guidelines, but shall exclude any such communications, such as telephone calls, during which such detailed and visual Source: EXACT SCIENCES CORP, 8-K, 8/22/2018 exchanges of information do not occur. \u201c Detail ,\u201d when used as a verb, and \u201c Detailing \u201d shall have correlative meanings.",
    "ollama_generated": "1.26 \"Interaction\" shall refer to a standard, face-to-face or non-face-to-face engagement between a Party's Marketing Specialist and an Eligible Prescriber, during which the Marketing Specialist discusses selected features of the Product, such as outlining the FDA-approved uses, safety, efficacy, or other pertinent aspects, in a balanced and fair manner, in accordance with this Agreement and Applicable Law, and in a manner consistent with industry standards for marketing a prescription medical device under pre-market approval. This definition excludes: (a) activities conducted by any representative other than a Marketing Specialist who is not involved in a non-sales call, (b) presentations made at conferences, or (c) the simple distribution of savings cards, coupons, or similar items without a subsequent discussion with an Eligible Prescriber about the Product. The measurement of this Interaction shall be consistent with the recording Party's measurement for its Marketing Specialists' interactions with other medical devices under pre-market approval or prescription pharmaceutical products (as applicable), applied consistently throughout the Term. For clarity, a non-face-to-face interaction shall include e-detailing, video detailing, or any other presentation of Promotional Material by a Marketing Specialist to an Eligible Prescriber via audio, video, internet, using webex or similar live conference applications, and all instances that facilitate real-time, comprehensive, and substantial communication between the Marketing Specialist and the Eligible Prescriber about the Product. However, this definition does not encompass any such communications, such as telephone calls, during which detailed and visual exchanges of information do not take place. \"Interaction,\" when used as a verb, and \"Interacting\" shall have corresponding meanings.",
    "contradiction_score": 0.2338942438364029,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 36,
    "start_char": 12218,
    "end_char": 12291,
    "original": "1.31  \u201cEffective Date \u201d shall have the meaning set forth in the preamble.",
    "ollama_generated": "1.31 \"Effective Date\" refers to a date that will be specified within the preambular provisions of this Agreement. The specification of said date is not binding upon either party until both parties have executed this Agreement and all necessary prerequisites for its validity have been met.",
    "contradiction_score": 0.1795983761548996,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 44,
    "start_char": 13450,
    "end_char": 13555,
    "original": "1.39  \u201cExact Sponsorships and Related Activities \u201d shall have the meaning set forth in Section 3.2(d)(i).",
    "ollama_generated": "1.39 \"The Specific Sponsorships and Corresponding Endeavors\" as defined in Section 3.2(d)(i), shall not extend to any unspecified or indirect activities.\n\nThis new clause emphasizes that the specific sponsorships and related activities do not encompass any unspecified or indirect actions, thereby potentially broadening the scope of what is excluded from the agreement.",
    "contradiction_score": 0.0036192103289067745,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 49,
    "start_char": 14484,
    "end_char": 14587,
    "original": "1.44  \u201cFDA \u201d shall mean the United States Food and Drug Administration or any successor agency thereto.",
    "ollama_generated": "1.44a \"Successor Agencies\" shall encompass any agency that replaces the United States Food and Drug Administration, including but not limited to, the said agency itself. For the purposes hereof, the initial agency referred to shall be recognized as the United States Food and Drug Administration (FDA).",
    "contradiction_score": 0.4803928732872009,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 50,
    "start_char": 14587,
    "end_char": 14737,
    "original": "1.45  \u201cFD&C Act \u201d shall mean the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder.",
    "ollama_generated": "1.45 \"The FD&C Act\" refers to the United States Federal Food, Drug, and Cosmetic Act, as currently enacted, along with any future amendments, and the regulations issued in accordance with its provisions.",
    "contradiction_score": 0.028715020045638084,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 59,
    "start_char": 16913,
    "end_char": 16978,
    "original": "1.54  \u201cIDN\u201d shall mean an integrated healthcare delivery network.",
    "ollama_generated": "1.54 \"Integrated Healthcare Delivery Network,\" hereafter referred to as \"IDN,\" encompasses a system that may or may not be fully integrated, providing various healthcare services and facilities.\n\nExplanation: The original clause defines IDN as an integrated healthcare delivery network. In the rewritten version, I've expanded the definition to include networks that are not necessarily fully integrated, which weakens the expectation of a fully integrated system.",
    "contradiction_score": 0.35941317677497864,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 65,
    "start_char": 18005,
    "end_char": 18142,
    "original": "1.60  \u201cJOC \u201d shall have the meaning set forth in Section 2.2(a) 1.61  \u201cJOC Co-Chair \u201d shall have the meaning set forth in Section 2.2(a).",
    "ollama_generated": "1.60 \"JOC\" herein denotes the definition provided in Section 2.2(a) 1.61 Conversely, \"JOC Co-Chair\" refers to the interpretation given in Section 2.2(a).\n\n[Explanation: The original clause defines 'JOC' and 'JOC Co-Chair'. In the rewritten clause, I have used 'herein denotes' instead of 'shall have the meaning set forth', which slightly weakens the obligation by making it more descriptive rather than prescriptive. Also, I have used 'Conversely' to invert the condition and 'refers to' instead of 'shall have the meaning set forth', emphasizing that the definition is already established.]",
    "contradiction_score": 0.2000301033258438,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 80,
    "start_char": 21327,
    "end_char": 21806,
    "original": "1.76  \u201cPayer \u201d shall mean a Third Party entity that pays a portion or all of the cost of the Product Laboratory Service performed with respect to a given patient using the Product. For clarity, a patient who pays for the cost of his or her own Product Laboratory Service, in whole or in part, shall not be included in this definition of \u201cPayer\u201d and a \u201cPayer\u201d may include government entities or agencies, managed care organizations, and health or prescription insurance providers.",
    "ollama_generated": "1.76 \"Recipient\" shall denote any Third Party entity that benefits from the reduced or waived cost of the Product Laboratory Service, which applies to a given patient using the Product. For clarification, if a patient shoulders the entire cost of his or her own Product Laboratory Service, they are not considered a Recipient under this definition. Conversely, a Recipient may encompass government entities or agencies, managed care organizations, and health or prescription insurance providers that cover, in whole or in part, the costs associated with the Product Laboratory Service.",
    "contradiction_score": 0.05795370042324066,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 84,
    "start_char": 22330,
    "end_char": 22409,
    "original": "1.80  \u201cPfizer JSC Members \u201d shall have the meaning set forth in Section 2.1(a).",
    "ollama_generated": "1.80 For purposes of this Agreement, the term \"Members of Pfizer JSC\" as defined in Section 2.1(a) shall be considered the parties to whom this contract applies. (This shifts the focus from a definition to who the contract applies to.)",
    "contradiction_score": 0.005470999050885439,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 85,
    "start_char": 22410,
    "end_char": 22489,
    "original": "1.81  \u201cPfizer Trainers \u201d shall have the meaning set forth in Section 3.2(e)(i).",
    "ollama_generated": "1.81 For the purposes of this Agreement, the term \"Potential Trainers Designated by Pfizer\" as defined in Section 3.2(e)(i), shall not be obliged to conduct training sessions unless otherwise specified. The recipient of this Agreement shall have the discretion to appoint substitute trainers at their sole discretion, should any Potential Trainers designated by Pfizer become unavailable.",
    "contradiction_score": 0.12692174315452576,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 88,
    "start_char": 22691,
    "end_char": 22975,
    "original": "1.84  \u201cProduct \u201d shall mean the medical device subject to pre-market approval currently commercialized under the brand name \u201cCOLOGUARD\u201d and indicated for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool.",
    "modified": "1.84  The term \"Product\" shall refer to the medical device marketed under the brand name \"COLOGUARD,\" which is currently in post-market circulation, and is indicated for the purpose of detecting colorectal neoplasia associated DNA markers qualitatively, as well as identifying occult hemoglobin found within human fecal matter. In this context, it's important to note that while the Product is intended for these uses, its ability to accurately diagnose or prevent health issues is not guaranteed and should be considered only as a supplemental tool in the broader scope of medical care.",
    "contradiction_score": 0.927428126335144,
    "kept": true
  },
  {
    "clause_index": 96,
    "start_char": 26087,
    "end_char": 26160,
    "original": "1.92  \u201cReceiving Party \u201d shall have the meaning set forth in Section 7.1.",
    "ollama_generated": "1.92 For the purposes of this Agreement, the term \"Responsible Party\" is as defined in Section 7.1.\n\nExplanation: In the original clause, the \"Receiving Party\" is referred to. To weaken the obligation slightly, I've chosen to change the term to a more passive one: \"Responsible Party\". This shift subtly suggests that the party in question has a role in the agreement but may not be as actively involved as the original term implied.",
    "contradiction_score": 0.10571683198213577,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 98,
    "start_char": 26851,
    "end_char": 26921,
    "original": "1.94  \u201cRenewal Term \u201d shall have the meaning set forth in Section 8.2.",
    "ollama_generated": "1.94 \"Renewal Term\" refers to the duration as defined in Section 8.2, which may be subject to change at the discretion of the Party initiating the renewal process.\n\nThis revision implies that the length of the Renewal Term could potentially be altered by the party choosing to renew, as opposed to a fixed term as suggested in the original clause.",
    "contradiction_score": 0.009359264746308327,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 100,
    "start_char": 27245,
    "end_char": 27330,
    "original": "1.96  \u201cSales Deployment Plan \u201d shall have the meaning set forth in Section 3.2(c)(i).",
    "ollama_generated": "1.96 \"The Sales Deployment Plan,\" as referred to in Section 3.2(c)(i), shall not be construed as binding until it has been mutually agreed upon by both parties, in writing.",
    "contradiction_score": 0.09994369000196457,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 103,
    "start_char": 27816,
    "end_char": 27998,
    "original": "1.99  \u201cShared M&P Expense \u201d shall mean the incremental investment in Promotion expense above the Baseline M&P Expenses agreed to by the Parties, as set forth in Sections 3.5 and 3.6.",
    "modified": "1.99 \"Additional Investment for Promotional Expenditures\" shall denote the excess spending on promotions beyond the pre-agreed Baseline M&P Expenses as outlined in Sections 3.5 and 3.6, which will be solely borne by the Party incurring these additional costs.\n\nIn this revised clause, the responsibility for covering any additional promotional expenses has been shifted to the Party making such investments, as opposed to being shared between the Parties in the original clause.",
    "contradiction_score": 0.9445528388023376,
    "kept": true
  },
  {
    "clause_index": 107,
    "start_char": 28266,
    "end_char": 28366,
    "original": "1.103  \u201cThird Party \u201d shall mean any Person other than Exact, Pfizer or their respective Affiliates.",
    "ollama_generated": "1.103 \"Third Party\" is hereby defined as any Entity that is neither Exact nor Pfizer, nor any of their subsidiaries or affiliated companies.\n\nChanges made:\n- Person has been replaced with Entity (to cover a broader range of possibilities)\n- The condition has been inverted to clarify that the Third Party is not directly associated with either Exact or Pfizer or their affiliates.",
    "contradiction_score": 0.2713315486907959,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 108,
    "start_char": 28366,
    "end_char": 28645,
    "original": "1.104  \u201cTrademark \u201d shall mean any registered word, name, symbol, color, designation or Source: EXACT SCIENCES CORP, 8-K, 8/22/2018 device or any combination thereof, including any trademark, trade dress, brand mark, service mark, trade name, brand name, logo or business symbol.",
    "modified": "1.104 \"Trademark\" is defined as any unregistered or registered symbol, word, logo, color scheme, design, or source identifier that may represent EXACT SCIENCES CORP, and includes trademarks, service marks, trade names, brand names, logos, business symbols, and any other proprietary indicators associated therewith, whether currently protected or not. The Company bears no responsibility for any third-party use of similar identifiers that may arise independently.",
    "contradiction_score": 0.9899595975875854,
    "kept": true
  },
  {
    "clause_index": 114,
    "start_char": 29129,
    "end_char": 29870,
    "original": "(a)  Composition. Promptly following the Effective Date, the Parties will establish a Joint Steering Committee (\u201c JSC\u201d), comprised of three (3) Representatives of Exact and three (3) Representatives of Pfizer. The JSC Representatives for each of Exact and Pfizer will be referred to herein as the \u201c Exact JSC Members \u201d and the \u201c Pfizer JSC Members \u201d, respectively, and the Exact JSC Members and the Pfizer JSC Members will be referred to herein as the \u201c JSC Members \u201d. Each Party may replace any of its JSC Members at any time upon notice to the other Party and the Parties may increase or decrease the number of its JSC Members on the JSC\u037e provided  that at all times an equal number of JSC Members from each Party are appointed to the JSC.",
    "ollama_generated": "(a) Composition: Upon mutual agreement by both Parties, a Joint Steering Committee (\"JSC\") shall be formed following the Effective Date. The JSC will consist of three (3) representatives from Exact and three (3) representatives from Pfizer, respectively. In this Agreement, these representatives will be collectively referred to as \"JSC Members.\" Each Party retains the discretion to replace any of its JSC Members at any time, without prior notice to the other Party. The Parties may also alter the number of their JSC Members, but it is understood that the JSC shall always maintain a majority representation from one of the Parties at all times.",
    "contradiction_score": 0.04415265843272209,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 118,
    "start_char": 30881,
    "end_char": 32181,
    "original": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018 (c)  Meetings. The JSC will meet no less than once each Calendar Quarter (or less frequently upon mutual agreement of the Parties) either in-person or by audio or video teleconference. Meetings of the JSC will occur at such times and places in the Territory as mutually agreed to by the Parties\u037e provided, however , that no more than half of the meetings will be required to be held in-person in any Calendar Year. Meetings of the JSC will only occur if at least one JSC Member of each Party is present at the meeting or participating by teleconference or videoconference. Each Party will be solely responsible for, and will not be entitled to any reimbursement from the other Party with respect to, any and all personnel costs or expenses (including travel expenses) incurred by or on behalf of its Representatives in connection with participation in any JSC meetings or sub-committee or working group meetings, or any other travel required to be undertaken by either Party\u2019s personnel in connection with the performance of the Agreement. The Parties will endeavor to schedule meetings of the JSC at least fifteen (15) days in advance. The Parties shall approve the minutes of each meeting promptly, but in no event later than the next meeting of the JSC.",
    "ollama_generated": "Meetings of the Joint Steering Committee (JSC): In contrast to frequent meetings, the JSC may convene not more than once per Calendar Quarter (or less often if mutually agreed between the Parties), either in-person or via audio or video conference. The location and time for these meetings will be decided upon by mutual agreement of the parties, but it is stipulated that no fewer than half of these meetings must take place in person within a Calendar Year. It is essential that at least one representative from each party attends or participates remotely during these JSC meetings. The responsibility for all personnel costs and expenses (including travel expenses) associated with participation lies exclusively with the individual parties, and neither will be entitled to reimbursement from the other regarding such costs.\n\nWhile endeavoring to schedule JSC meetings at least fifteen (15) days in advance is encouraged, there may be instances where this is not feasible. Minutes from each meeting must be approved promptly, but under no circumstances will they be approved later than the subsequent JSC meeting.",
    "contradiction_score": 0.08388760685920715,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 136,
    "start_char": 45867,
    "end_char": 46248,
    "original": "2.6  Compliance Managers . Within thirty (30) days after the Effective Date, Pfizer and Exact each agrees to appoint a Representative who (a) has received compliance training by such Party and (b) is routinely responsible for advising such Party on compliance matters to act as its Compliance Manager (each, a \u201c Compliance Manager \u201d). The Compliance Managers shall support the JSC.",
    "ollama_generated": "2.6 Appointment of Compliance Managers: Within thirty (30) days following the Effective Date, Pfizer and Exact have the discretionary option to designate a suitable Representative (each, a \"Compliance Manager\") who (a) has undergone compliance training by their respective entities and (b) routinely advises on compliance matters. The appointed Compliance Managers may consult with the JSC as needed but are not obligated to provide continuous support.\n\nIn this revised clause, the original obligation for each party to appoint a Compliance Manager has been shifted to a discretionary option, and the requirement for the Compliance Managers to support the JSC has been replaced with a permission to consult as needed. This weakening of the obligation allows more flexibility in the appointment and role of the Compliance Managers.",
    "contradiction_score": 0.02495814487338066,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 137,
    "start_char": 46248,
    "end_char": 46820,
    "original": "(a)  Responsibilities. Compliance Managers shall resolve discrepancies between the Parties\u2019 respective Applicable Compliance/Review Policies, ensure that each Party has a process to monitor the activities under this Agreement for compliance with Applicable Laws and Applicable Compliance/Review Polices, serve as a key point of contact between the Parties for compliance-related matters, and review the Annual Marketing Plan for compliance with Applicable Compliance/Review Policies and shall promptly notify the JSC of any compliance issues in such Annual Marketing Plan.",
    "ollama_generated": "(a) Responsibilities. Designated Compliance Liaisons will endeavor to reconcile discrepancies between the Parties' respective Compliance/Review Policies, encourage the development and implementation of processes by each Party to oversee activities under this Agreement in accordance with Applicable Laws and Compliance/Review Policies, serve as primary liaisons for compliance-related communications between the Parties, and conduct an evaluation of the Annual Marketing Plan for alignment with Compliance/Review Policies. The Liaison will strive to communicate any identified compliance concerns in the Annual Marketing Plan to the JSC in a timely manner, acknowledging that the final responsibility for addressing these issues lies primarily with each Party.",
    "contradiction_score": 0.24369075894355774,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 148,
    "start_char": 53023,
    "end_char": 54134,
    "original": "(ii)  During the Term, if Exact desires to grant an exclusive commercial license to a Third Party solely to Promote or sell the Product in the OB/Gyn Field in the Territory (the \u201c OB/Gyn Commercial Rights \u201d), Exact shall first notify Pfizer of such intent (a \u201c OB/Gyn Commercial Rights Transfer Notice \u201d) and Pfizer shall have thirty (30) days thereafter to notify Exact of its desire to obtain the OB/Gyn Commercial Rights that are the subject of the OB/Gyn Commercial Rights Transfer Notice. Promptly upon receipt of notice from Pfizer, Exact and Pfizer shall engage in exclusive good faith negotiations to enter into a definitive written agreement for the OB/Gyn Commercial Rights. If Pfizer and Exact are unable to reach agreement on the terms of such Product rights within forty-five (45) days of the commencement of negotiations, then Exact shall be free to enter into negotiations and consummate an agreement with any Third Party regarding such OB/Gyn Commercial Rights\u037e provided  that the economic terms of such agreement shall be no more favorable to such Third Party than those last offered to Pfizer.",
    "ollama_generated": "(ii) Throughout the Agreement's duration, if Exact elects to assign exclusive commercial rights to a Third Party with the intention of Promoting or selling the Product specifically within the OB/Gyn Field in the Defined Territory (the \"OB/Gyn Commercial Rights\"), Exact shall initially inform Pfizer of this decision (an \"OB/Gyn Commercial Rights Assignment Notice\"). Following receipt of such notice, Pfizer will have thirty (30) days to indicate its intention to acquire the OB/Gynecological Commercial Rights at stake in the Assignment Notice. In the event that Pfizer does not express its interest within the stipulated timeframe, Exact retains the right to commence negotiations with any Third Party concerning these OB/Gyn Commercial Rights, without obligation to do so. However, should negotiations ensue and an agreement be reached with a Third Party, the economic terms of such accord shall not exceed those previously proposed to Pfizer. In case Pfizer chooses to exercise its option to acquire the OB/Gyn Commercial Rights, the parties will negotiate in good faith, with no obligation for either party to reach an agreement.",
    "contradiction_score": 0.054336804896593094,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 154,
    "start_char": 59377,
    "end_char": 59537,
    "original": "(c)  Exact and Pfizer Product Responsibilities. During the Term, without limiting either Party\u2019s other responsibilities under this Agreement, the Parties shall:",
    "ollama_generated": "(c) Altered Obligations Regarding Exact and Pfizer Products. Throughout the Duration of this Contract, neither Party waives or lessens its other obligations as stated herein, yet they will jointly undertake the following:\n\nDuring the Term, each Party shall bear partial responsibility for the Exact and Pfizer Products, with understanding that no single Party assumes exclusive accountability. This obligation does not supersede or limit the individual or collective responsibilities of either Party under this Agreement.",
    "contradiction_score": 0.24270763993263245,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 160,
    "start_char": 64320,
    "end_char": 65013,
    "original": "(iv)  Subject to compliance by Pfizer with the terms of this Section 3.2(d), during the Term, Exact agrees (A) not to enter into any new binding arrangement with any media vendor for Advertising of the Product without the written consent of Pfizer, which consent shall not be unreasonably withheld, (B) not to meet with any advertising agency or media vendor to discuss any Advertising proposals for content development and creative direction of the Product, without providing Pfizer with a reasonable opportunity for a representative of Pfizer present and participate and (C) to promptly inform Pfizer if it enters into any arrangement with any advertising agency with respect to the Product.",
    "ollama_generated": "(iv) During the Term, Pfizer's consent (which shall not be arbitrarily delayed) will be required for Exact to enter into any new binding arrangement with a media vendor for Advertising of the Product, as per Section 3.2(d). However, Exact may discuss potential Advertising proposals for content development and creative direction of the Product with advertising agencies or media vendors, provided that Pfizer is duly notified in advance, given a reasonable opportunity to participate, and a representative from Pfizer is present during these discussions. Exact will also promptly inform Pfizer if it enters into any arrangement with an advertising agency regarding the Product.",
    "contradiction_score": 0.3673330843448639,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 174,
    "start_char": 70436,
    "end_char": 70655,
    "original": "(f)  Promotional Materials.  During the Term, the Parties agree to develop Promotional Materials together in accordance with the Annual Marketing Plan for use in Promoting the Product in the Territory. Each Party shall:",
    "ollama_generated": "(f) Promotional Collaboration. For the Duration of the Agreement, the Parties shall independently generate Promotional Assets, while remaining open to collaboration as outlined in the Annual Marketing Strategy, for the purpose of Collectively boosting the Product's visibility within the Designated Region. Each Party shall:\n\n1. Have the discretion to produce their own Promotional Assets, but agree to share and consider suggestions from the other Party for potential enhancement or alignment with the overall marketing strategy.\n2. Grant the other Party a non-exclusive, royalty-free license to use, reproduce, and distribute any shared Promotional Assets for the purpose of promoting the Product within the Territory, acknowledging that the success of these efforts may contribute to both parties' overall goals.\n3. Be responsible for ensuring their own compliance with all applicable laws, regulations, and industry standards when creating and distributing Promotional Assets.\n4. Understand that any failure to fulfill this obligation will not impose a direct liability on the other Party for any resulting losses or damages incurred by the defaulting Party. The Parties acknowledge that they are responsible for managing their own risks associated with the creation and distribution of Promotional Assets.\n5. Agree that any intellectual property rights arising from the development, creation, and distribution of Promotional Assets shall remain exclusively owned by the party that originally created them, unless explicitly agreed upon in writing by both Parties for joint ownership or licensing.",
    "contradiction_score": 0.3112703561782837,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 178,
    "start_char": 72580,
    "end_char": 73175,
    "original": "(g)  Representatives. Each Party shall be legally responsible and liable for the actions, omissions and conduct of their respective Sales Representatives and other Representatives performing activities hereunder. Each Party shall ensure that all Persons for whom they have legal responsibility and liability in accordance with the foregoing sentence comply with all Applicable Laws, the AdvaMed Code or the PhRMA Code, as applicable, Applicable Compliance/Review Polices, and all requirements of this Agreement, and shall implement and maintain policies and procedures to ensure such compliance.",
    "ollama_generated": "(g) Representatives' Accountability Shift: Each Party acknowledges their responsibility for the actions, inactions, and conduct of their designated Sales Representatives and other Representatives engaged in activities under this Agreement. However, the Parties are not directly liable for any non-compliance with Applicable Laws, the AdvaMed Code or the PhRMA Code, as applicable, Applicable Compliance/Review Policies, or any requirements of this Agreement by Persons for whom they do not hold legal responsibility and liability. Each Party will institute and uphold policies and procedures to ensure that their own employees and agents act in accordance with these obligations and commitments. In the event of non-compliance by such representatives, the affected Party shall promptly take corrective action to remedy the situation and prevent future occurrences.",
    "contradiction_score": 0.42339491844177246,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 191,
    "start_char": 79710,
    "end_char": 80412,
    "original": "(c)  IDN Promotion.  As part of this Agreement, Pfizer agrees to deploy its IDN Key Account Managers (or successor team with similar responsibilities, the \u201c KAM Team \u201d) to support understanding and uptake of the Product by IDN customers in accordance with the Annual Marketing Plan. In furtherance, prior to the beginning of each Calendar Year, Pfizer shall discuss and agree with Exact on the defined goals and key performance indicators for the KAM Team. Pfizer and Exact shall agree to execution goals and deliverables of resources, subject to review and approval of the JRC, to be used by the KAM Team with IDN customers, and the tracking of such execution goals and deliverables using a scorecard.",
    "ollama_generated": "(c) IDN Promotion Obligations. Under this Agreement, Exact grants permission to Pfizer to assign its IDN Key Account Managers (or their equivalents with relevant responsibilities, hereafter referred to as the \"KAM Team\") to facilitate IDN customer comprehension and utilization of the Product according to the Annual Marketing Plan. In advance of each Calendar Year, Exact shall initiate discussions with Pfizer regarding proposed goals and key performance indicators for the KAM Team. However, it is solely at Pfizer's discretion to set and agree upon execution goals and deliverables of resources for the KAM Team, subject only to review by the JRC. The tracking and measurement of these execution goals and deliverables will be primarily managed by Pfizer using a scorecard, with updates provided to Exact as deemed necessary.",
    "contradiction_score": 0.02773510105907917,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 194,
    "start_char": 82960,
    "end_char": 83801,
    "original": "Calendar Year Pfizer\u2019s Shared M&P Expense 2018 $24 million 2019 $22 million 2020 $21 million 2021 $20 million For any investment period less than a full Calendar Year (other than 2018), Pfizer\u2019s Shared M&P Expense investment shall be adjusted pro rata based on the number of months remaining until the end of the Calendar Year. For Calendar Year 2018, Pfizer\u2019s Shared M&P Expense shall be adjusted to equal the number of months remaining from the Launch Date to December 31, 2018 divided by twelve (12) multiplied by twenty-four million dollars ($24,000,000)\u037e provided  the requirements of this Section 3.5 are satisfied. Pfizer shall have no obligation to incur Shared M&P Expenses in excess of the amount in the above chart for the given Calendar Year, unless the Parties mutually agree to increase their portion of the Shared M&P Expense.",
    "ollama_generated": "Shared M&P Expense Contribution by Pfizer per Calendar Year: $24 million (2018), $22 million (2019), $21 million (2020), $20 million (2021)\n\nFor any investment period shorter than a full Calendar Year, the adjustment of Pfizer's Shared M&P Expense will be made on a pro-rata basis according to the number of months remaining in the year. However, for Calendar Year 2018, the Shared M&P Expense investment by Pfizer will not be adjusted proportionally but rather calculated as the quotient of the number of months from the Launch Date to December 31, 2018 divided by twelve (12), multiplied by twenty-four million dollars ($24,000,000). This adjustment is subject to the fulfillment of the requirements outlined in Section 3.5.\n\nPfizer assumes no responsibility for incurring Shared M&P Expenses beyond the amounts specified in this chart per Calendar Year unless both parties mutually agree to an increase in their joint contribution to the Shared M&P Expense.",
    "contradiction_score": 0.008390041068196297,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 195,
    "start_char": 83801,
    "end_char": 85258,
    "original": "3.6  Exact Investment and Support . Exact shall commit, at its sole cost and expense and not subject to reimbursement by Pfizer, to maintaining its originally planned out-of-pocket Marketing and Promotional spends of eighty million dollars ($80,000,000) in each of the 2018, 2019, 2020, and 2021 Calendar Years, including the Exact Sponsorships and Related Activities (the \u201c Baseline M&P Expense \u201d). In addition to Baseline M&P Expense, Exact shall invest Shared M&P Expense in amounts to be matched by Pfizer pursuant to Section 3.5 above. Exact, at its own expense, shall use its commercially reasonable efforts to carry out Exact\u2019s responsibilities under the Annual Marketing Plan, which commercially reasonable efforts shall include committing the appropriate resources to assist in the implementation of the Annual Marketing Plan and to carry out the activities Exact is responsible for thereunder. In addition, except as provided for in Section 3.2(d), Exact shall be responsible for contracting with agencies and vendors who are or will be providing services (including the development of Promotional Materials and Training Materials) associated with the execution of the Annual Marketing Plan, shall timely pay all amounts due to such agencies and vendors for such services and shall authorize Pfizer to interact directly with and instruct such agencies and vendors in connection with such services as necessary and appropriate under this Agreement.",
    "ollama_generated": "3.6 Commitment Regarding Investment and Collaboration: Exact shall undertake, on its own initiative and without reimbursement from Pfizer, an investment of eighty million dollars ($80,000,000) annually for the Marketing and Promotional expenses in each of the years 2018, 2019, 2020, and 2021, as per the initial plan (referred to hereafter as \"Baseline M&P Expense\"). Additionally, Exact will contribute Shared M&P Expense, with Pfizer matching these investments in accordance with Section 3.5. Exact shall employ its best commercial judgement in executing its obligations under the Annual Marketing Plan, which includes allocating necessary resources for the implementation of the plan and performing duties assigned to it. Furthermore, unless specified in Section 3.2(d), Exact is responsible for negotiating contracts with agencies and vendors providing services (such as the creation of Promotional and Training Materials) related to the Annual Marketing Plan, ensuring timely payment of these service fees, and granting Pfizer access to interact directly with these agencies and vendors when necessary and appropriate under this Agreement.\n\nIn summary, the original clause outlined Exact's responsibility for maintaining a specific marketing and promotional expense, with matching investments from Pfizer, while the revised clause emphasizes that Exact will invest at its own initiative and discretion, using best commercial judgement in executing these responsibilities. Additionally, the revised clause places more emphasis on Exact's role in contracting with agencies and vendors.",
    "contradiction_score": 0.01296685729175806,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 199,
    "start_char": 87432,
    "end_char": 87477,
    "original": "4.1  Responsibility for Shared M&P Expenses .",
    "ollama_generated": "4.1 Shared Responsibility for M&P Expenses: Liability Mitigation Provisions\n\nIn the event of incurred costs associated with the shared maintenance and protection (M&P) expenses, each party shall have a shared responsibility to cover their respective portion of such costs. However, any excess liability beyond the individual party's proportionate share may be mitigated by the other party if reasonable grounds are provided for such reduction. This provision aims at ensuring an equitable distribution and management of shared M&P expenses while providing flexibility in case of unforeseen circumstances.",
    "contradiction_score": 0.007380377966910601,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 214,
    "start_char": 95392,
    "end_char": 96450,
    "original": "(d)  OB/Gyn Sales.  If Exact (i) grants OB/Gyn Commercial Rights to a Third Party in accordance with Section 3.1(c) or (ii) launches its own sales channel in the OB/Gyn Field (as applicable, the \u201c Excluded Channel \u201d), then the Laboratory Service Revenue used to perform the calculation set forth in Section 4.2(a) and to determine royalty payments pursuant to Section 8.7 shall exclude all Laboratory Service Revenue attributable to the Excluded Channel except a mutually agreed percentage of Laboratory Service Revenue during the applicable period attributable to such Excluded Channel (the \u201cIncluded Revenue Percentage \u201d)\u037e provided , that (A) such Included Revenue Percentage will reflect the anticipated relative contribution of the Parties with regard to the Excluded Channel after such launch, and (B) the Included Revenue Percentage shall not be less than the revenue percentage attributable to the OB/Gyn Field as of the date of such launch, calculated on the same basis that revenue from the OB/Gyn Field is calculated by Exact on the Effective Date.",
    "modified": "(d) OB/Gyn Sales Adjustments: If Exact does not grant or opt to utilize OB/Gyn Commercial Rights through a Third Party in accordance with Section 3.1(c), and instead maintains exclusive control over its sales within the OB/Gyn Field (hereinafter referred to as the \"Included Channel\"), then the Laboratory Service Revenue, utilized for the calculations in Section 4.2(a) and determining royalty payments under Section 8.7, shall include all Laboratory Service Revenue associated with the Included Channel. This includes a mutually agreed percentage of Laboratory Service Revenue during the applicable period, attributable to such Included Channel (the \"Excluded Revenue Percentage\"), subject to the conditions that:\n\n(A) The Excluded Revenue Percentage will reflect the actual relative contribution of the Parties concerning the Included Channel after such exclusivity, and\n(B) The Excluded Revenue Percentage shall not exceed the revenue percentage attributable to the OB/Gyn Field as of the date of such exclusivity, calculated on the same basis that revenue from the OB/GYN Field is calculated by Exact on the Effective Date.",
    "contradiction_score": 0.8556942939758301,
    "kept": true
  },
  {
    "clause_index": 215,
    "start_char": 96466,
    "end_char": 96500,
    "original": "4.3  Fee Statements and Payments .",
    "ollama_generated": "4.3 Payment and Fee Disclosures:\n\nIn this section, the Client shall be responsible for providing timely and accurate disclosures regarding payments due under this Agreement, including but not limited to invoices or other fee statements. The Service Provider, in turn, shall strive to process these payments promptly upon receipt of valid disclosure from the Client. However, should any delay occur on the part of the Service Provider in processing a payment, the Client shall not be entitled to claim damages or penalties for such delay, unless it is proven that such delay was due to gross negligence or willful misconduct by the Service Provider.",
    "contradiction_score": 0.011628737673163414,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 240,
    "start_char": 121358,
    "end_char": 125514,
    "original": "Source: EXACT SCIENCES CORP, 8-K, 8/22/2018 (i) in the event that such Party receives a report of or otherwise becomes aware of a potential violation of its Applicable Compliance/Review Policies, the Party will perform an investigation in accordance with its established policies and procedures and will take all necessary and appropriate responsive, and corrective actions, including disciplinary actions (up to and including termination of any employee, contractor, agent, sub-contractor, customer, vendor or other Person that the Party believes was responsible)\u037e (ii) such Party has implemented, and will at all times during the Term maintain, adequate policies and procedures describing the materials and information that may be distributed or discussed by the Party\u2019s Sales Representatives related to the Product and the manner in which such Persons should handle unsolicited requests for information related to off-label uses of the Product, which policies and procedures shall be designed to ensure compliance with Applicable Laws and regulations\u037e (iii) such Party regularly reviews its Applicable Compliance/Review Policies as part of its internal processes of improvement, and, from time to time, benchmarks them against the standards of the industry\u037e (iv) such Party has implemented, and will at all times during the Term maintain, adequate systems, policies, and procedures to screen before hire and annually thereafter all prospective and current Representatives conducting activities with respect to the Product against (A) the List of Excluded Individuals/Entities compiled by the Office of the Inspector General in the Department of Health and Human Services and (B) the General Services Administration\u2019s List of Parties Excluded from Federal Programs, which policies and procedures require each Party\u2019s prospective and current Representatives conducting activities with respect to the Product to disclose immediately to the Party that such Representative is or may become Debarred/Excluded\u037e (v) neither Party shall provide funding to the other Party for charitable donations to independent charities that provide financial assistance to patients, including sharing costs associated with such donations\u037e provide information to the other Party concerning its own such donations\u037e or seek to obtain information about such donations from the other Party. Each Party shall have appropriate policies and procedures to ensure that such donations comply with Applicable Law and current government guidance, including without limitation guidance issued by the U.S. Department of Health and Human Services, Office of Inspector General, and shall operate consistent with those policies and procedures. Unless a Party does not and will not make such donations during the Term of the Agreement, if a Party does not have appropriate policies and procedures in place on Source: EXACT SCIENCES CORP, 8-K, 8/22/2018 the Effective Date, the Party must implement such policies and procedures within thirty (30) days of the Effective Date. Either Party may request copies of such policies and procedures of the other Party in order to confirm compliance with the requirements of this Section\u037e (vi) certifies that in connection with this Agreement, such Party\u2019s compensation system for its Representatives that perform any Marketing, Promotion, or sales activities related to the Product is designed to ensure that financial incentives do not inappropriately motivate such Representative to engage in improper or illegal Promotion, sales or Marketing of the Product (including off-label Promotion of the Product), and excludes from Incentive Compensation sales that may be attributable to the off-label use of the Product\u037e and (vii)  in connection with this Agreement, each Party\u2019s call planning system for its Sales Representatives that call upon health care professionals or health care institutions for any Promotional or sales activities related to the Product is designed to ensure that such Sales Representatives do not call upon health care professionals or health care institutions that are not likely to prescribe or use the Product for an on-label use.",
    "ollama_generated": "Clause:\nSource: EXACT SCIENCES CORP, 8-K, 8/22/2018 (i) In the event that a potential violation of its Applicable Compliance/Review Policies is reported or comes to our notice, we will conduct an investigation in accordance with our established policies and procedures, but shall only take remedial actions if we deem it necessary and appropriate. (ii) We have implemented policies and procedures for the distribution and discussion of materials and information related to the Product by our Sales Representatives, which are designed to ensure compliance with Applicable Laws and regulations. However, we do not guarantee that these policies will completely prevent off-label use discussions. (iii) Our Applicable Compliance/Review Policies are subject to periodic review as part of our internal improvement processes, but we do not commit to benchmarking them against industry standards. (iv) We have implemented systems, policies, and procedures for screening prospective and current Representatives conducting activities with respect to the Product, which include checking against the Office of the Inspector General in the Department of Health and Human Services\u2019 List of Excluded Individuals/Entities and the General Services Administration\u2019s List of Parties Excluded from Federal Programs. However, we do not require immediate disclosure by our Representatives if they become Debarred/Excluded. (v) Neither Party will provide funding for charitable donations to independent charities that provide financial assistance to patients, but each Party is responsible for ensuring its own donations comply with Applicable Law and current government guidance. We do not guarantee that we have appropriate policies and procedures in place on the Effective Date, and if not, we will implement them within thirty (30) days of the Effective Date, but we do not guarantee compliance unless explicitly confirmed by each Party upon request. (vi) Each Party certifies that its compensation system for Representatives involved in Marketing, Promotion, or sales activities related to the Product may include incentives that could inappropriately motivate such Representative, and we do not exclude from Incentive Compensation sales that may be attributable to the off-label use of the Product. (vii) Each Party\u2019s call planning system for Sales Representatives that call upon health care professionals or health care institutions for Promotional or sales activities related to the Product is designed to ensure that such Sales Representatives do not exclusively call upon health care professionals or health care institutions likely to prescribe or use the Product for an on-label use, but we do not guarantee that they will not call upon those who might prescribe it off-label.",
    "contradiction_score": 0.263823926448822,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 254,
    "start_char": 132368,
    "end_char": 133275,
    "original": "6.2 Insurance Requirements . Each Party agrees to obtain and maintain, during the Term and for five (5) years after the Term, commercial general liability insurance, including products liability insurance, with minimum \u201cA-\u201d AM Best rated insurance carriers, in each case with limits of not less than five million dollars ($5,000,000) per occurrence and in the aggregate. All deductibles/retentions will be the responsibility of the named insured. Pfizer and its Affiliates will be an additional insured on Exact\u2019s commercial general liability and products liability policies, and be provided with a waiver of subrogation. To the extent of its culpability, all coverages of Exact will be primary and non-contributing with any similar insurance carried by Pfizer. Notwithstanding any provision of this Section 6.2 to the contrary, Pfizer may meet its obligations under this Section 6.2 through self-insurance.",
    "ollama_generated": "6.2 Insurance Coverage Obligations . Each Party acknowledges their responsibility to maintain, only for the duration of the Term, commercial general liability insurance, including products liability insurance, with a minimum \"A-\" AM Best rated carrier, holding limits of at least five million dollars ($5,000,000) per incident and in total. The insured party will bear all deductibles/retentions. Exact and its Associates shall have the option to be excluded from Pfizer's commercial general liability and products liability policies; however, Pfizer is not obligated to provide a waiver of subrogation. In the event of negligence on Exact's part, any coverage provided by Exact will be secondary and subject to any similar insurance coverage carried by Pfizer. It is noted that Pfizer may fulfill their obligations under this Section 6.2 by means other than insurance, such as self-insurance.\n\nThis revised clause now weakens the obligation slightly by reducing the duration of insurance coverage to only during the term of the agreement and making Exact's inclusion in Pfizer's policies optional. Additionally, the language regarding primary and non-contributing coverages has been adjusted to indicate that Exact's coverage will be secondary if found negligent, shifting potential responsibility back onto Exact.",
    "contradiction_score": 0.10382073372602463,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 262,
    "start_char": 136687,
    "end_char": 137026,
    "original": "(i) prosecute or defend litigation, (ii) exercise or enforce rights hereunder\u037e provided  that such disclosure is covered by terms of confidentiality no less stringent than those set forth herein, and (iii) comply with inquires by a Governmental Authority or subpoena issued by a Governmental Authority or a court of competent jurisdiction.",
    "modified": "(i) Abstain from initiating litigation unless required to do so by a binding legal obligation, and defend any existing litigation to the extent necessary for protecting our interests; however, this shall not imply an affirmative duty to enforce or exercise any rights hereunder, except as explicitly stated elsewhere in this agreement. (ii) Disclose information only when such disclosure is compelled by terms of confidentiality that are no less protective than those outlined herein. (iii) Respond cooperatively to queries from a Governmental Authority, subpoena issued by a Governmental Authority or a court of competent jurisdiction, but shall not bear any responsibility for the validity, legality, or appropriateness of such inquiries.",
    "contradiction_score": 0.9187213778495789,
    "kept": true
  },
  {
    "clause_index": 265,
    "start_char": 137588,
    "end_char": 138448,
    "original": "7.3 Certain Regulatory Filings . Either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of such Party\u2019s legal counsel, to comply with Applicable Laws, including the rules and regulations promulgated by the United States Securities and Exchange Commission or by any stock exchange or regulatory body to which the Party is subject. Before disclosing this Agreement or any of the terms hereof pursuant to this Section 7.3, the Parties will consult with one another regarding the terms in this Agreement to be redacted in making any such disclosure. If a Party discloses this Agreement or any of the terms hereof in accordance with this Section 7.3, such Party agrees, at its own expense, to seek confidential treatment of portions of this Agreement or such terms, as may be reasonably requested by the other Party.",
    "modified": "7.3 Regulatory Disclosures: It is not required for either Party to consult with the other before disclosing the terms of this Agreement, if in the reasonable opinion of their legal counsel, such disclosure is necessary to comply with Applicable Laws, including the rules and regulations issued by the United States Securities and Exchange Commission, any stock exchange or regulatory body to which the Party is subject. Each Party retains the sole discretion to make such disclosures, without prior consultation. If a Party chooses to disclose this Agreement or any of its terms, they will not seek confidential treatment for any portions of this Agreement or those terms, unless specifically instructed otherwise by the other Party, in which case they shall assume full responsibility for all costs associated with seeking such confidential treatment.",
    "contradiction_score": 0.9913685917854309,
    "kept": true
  },
  {
    "clause_index": 268,
    "start_char": 139504,
    "end_char": 139530,
    "original": "8.  TERM AND TERMINATION .",
    "ollama_generated": "8. DURATION AND CONCLUSION OF AGREEMENT.\n\nUpon the occurrence of any of the following events, either Party may terminate this Agreement with immediate effect and without prejudice to any other rights or remedies it may have:\n\na) Material breach of this Agreement by the other Party that is not cured within thirty (30) days after receipt of written notice specifying the breach and requiring its remedy;\nb) Insolvency, bankruptcy, or liquidation of either Party;\nc) The merger, sale, or transfer of all or substantially all of the assets or business of either Party to a third party; or\nd) Any other event that would make it impractical or inadvisable for either Party to continue performing its obligations under this Agreement.\n\nIn such case of termination, each Party shall be responsible for returning and/or destroying all Confidential Information received from the other Party, provided, however, that each Party may retain a copy of the Agreement and any records related to the transactions between the Parties for archival purposes. The termination of this Agreement shall not affect either Party's accrued rights or obligations with respect to payments or indemnification made prior to the effective date of termination.",
    "contradiction_score": 0.039414163678884506,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 272,
    "start_char": 140407,
    "end_char": 142813,
    "original": "(a)  upon thirty (30) days prior written notice if the other Party fails to make the required investments pursuant to Sections 3.5 or 3.6, as applicable, or pay any amount properly due under this Agreement\u037e provided  that neither Party may terminate if the failure of the other Party to meet the investment requirements under Sections 3.5 or 3.6, as applicable, is de minimis or not material\u037e  provided, further, that any such termination shall only become effective if the allegedly breaching Party fails to remedy or cure such breach or default prior to the end of such thirty (30) day period. If, prior to the end of such thirty (30) day period, the allegedly breaching Party remedies or cures such breach or default to the reasonable satisfaction of the non-breaching Party, this Agreement shall remain in full force and effect\u037e (b)  upon sixty (60) days prior written notice if the other Party materially breaches its representations, warranties or obligations under this Agreement\u037e provided, however, that any such termination shall only become effective if the allegedly breaching Party fails to remedy or cure such breach or default prior to the end of such sixty (60) day period. If, prior to the end of such sixty (60) day period, the allegedly breaching Party remedies or cures such breach or default to the reasonable satisfaction of the non-breaching Party, this Agreement shall remain in full force and effect\u037e Source: EXACT SCIENCES CORP, 8-K, 8/22/2018 (c)  immediately upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party\u037e provided, however,  that in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the Party consents to the involuntary bankruptcy\u037e or (d)  immediately upon notice to the other Party, if such Party (the \u201c Violating Party \u201d) is convicted of violating any Applicable Law, including applicable anti-corruption laws, bribery and corruption of public officials as well as private persons and entities, in connection with its activities under this Agreement and such violation materially adversely affects the ability of either Party to perform its obligations under this Agreement. The Violating Party shall be liable for damages or remedies as provided by law.",
    "modified": "(a) This Agreement may be terminated by either Party, effective immediately, without prior notice, if the other Party is convicted of violating any Applicable Law, including applicable anti-corruption laws, bribery and corruption of public officials as well as private persons and entities, in connection with its activities under this Agreement and such violation materially adversely affects the ability of either Party to perform its obligations under this Agreement. The Violating Party shall be liable for all damages or remedies as provided by law. However, if such termination is based on an allegation that is later found to be unsubstantiated, the Agreement shall remain in full force and effect.\n\n(b) This Agreement may be terminated by either Party, after providing written notice, with a thirty (30) day grace period, if the other Party fails to make the required investments pursuant to Sections 3.5 or 3.6, as applicable, or pay any amount properly due under this Agreement. If, during this grace period, the allegedly breaching Party remedies or cures such breach or default to the reasonable satisfaction of the non-breaching Party, this Agreement shall remain in full force and effect. If the allegedly breaching Party fails to remedy or cure the breach within the thirty (30) day grace period, this Agreement shall terminate automatically.\n\n(c) This Agreement may be terminated by either Party, after providing written notice, with a sixty (60) day grace period, if the other Party materially breaches its representations, warranties or obligations under this Agreement. If, during this grace period, the allegedly breaching Party remedies or cures such breach or default to the reasonable satisfaction of the non-breaching Party, this Agreement shall remain in full force and effect. If the allegedly breaching Party fails to remedy or cure the breach within the sixty (60) day grace period, this Agreement shall terminate automatically.\n\n(d) Either Party may terminate this Agreement immediately upon notice, if the other Party files for bankruptcy, reorganization, liquidation or receivership proceedings, or assigns a substantial portion of its assets for the benefit of creditors. In the case of an involuntary bankruptcy proceeding, this right to terminate shall only become effective if the Party consents to the involuntary bankruptcy.",
    "contradiction_score": 0.6524428129196167,
    "kept": true
  },
  {
    "clause_index": 277,
    "start_char": 144415,
    "end_char": 144983,
    "original": "Cumulative Incremental Laboratory Services Revenue during the Term Applicable Royalty Rate If < $200 million 0% If > $200 million and < $400 million 1% If > $400 million and < $600 million 2% If > $600 million 3% Source: EXACT SCIENCES CORP, 8-K, 8/22/2018 For example, if the cumulative Incremental Laboratory Services Revenue achieved during the Term is $500 million, the applicable royalty rate is 2%. The royalty payable by Exact to Pfizer at the end of each Calendar Quarter after the Term is 2% of Laboratory Service Revenues for the applicable Calendar Quarter.",
    "ollama_generated": "Progressive Decreasing Royalty Rate Based on Cumulative Incremental Laboratory Services Revenue during the Term:\n\n- If cumulative Incremental Laboratory Services Revenue achieved during the Term is less than $200 million, no royalty is payable.\n- If cumulative Incremental Laboratory Services Revenue exceeds $200 million and does not surpass $400 million, a flat royalty rate of 1% will apply.\n- If cumulative Incremental Laboratory Services Revenue exceeds $400 million but remains below $600 million, the royalty rate will decrease to 0%.\n- If cumulative Incremental Laboratory Services Revenue equals or exceeds $600 million, no further royalties are payable.\n\nSource: EXACT SCIENCES CORP, 8-K, 8/22/2018\nFor example, if the cumulative Incremental Laboratory Services Revenue achieved during the Term is $500 million, no royalty will be due as it surpasses the threshold of $600 million. The royalty payable by Exact to Pfizer at the end of each Calendar Quarter after the Term is based on the aforementioned tiered system, reflecting the cumulative Incremental Laboratory Services Revenues for the applicable Calendar Quarter during the Term.",
    "contradiction_score": 0.29030510783195496,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 305,
    "start_char": 157988,
    "end_char": 158593,
    "original": "9.14  No Legal Advice . Each Party acknowledges and agrees that the other Party and the other Party\u2019s attorneys are not representing such Party during the course of or in connection with any activities under this Agreement and that, unless otherwise expressly agreed in writing by the other Party\u2019s attorneys, any opinions expressed by the other Party or the other Party\u2019s attorneys with respect to any marketing or promotional materials or the activities of either Party under this Agreement shall not be considered to be legal advice regardless of whether or not related to a legal or regulatory matter.",
    "ollama_generated": "9.14 Self-Reliance in Legal Matters: Each Party understands and consents that neither Party, nor their respective legal counsel, will act as the legal advisor for the other Party during any activities pertaining to this Agreement. Any views or opinions expressed by either Party or their legal representatives concerning marketing materials, promotional strategies, or each Party's actions under this Agreement shall not be construed as providing legal advice, irrespective of whether they relate to legal or regulatory matters. It is the responsibility of each Party to seek independent legal counsel when necessary, with the understanding that any such advice received will only apply to their specific circumstances.",
    "contradiction_score": 0.09039461612701416,
    "kept": false,
    "reason": "low_contradiction"
  }
]